Development of a Polygenic Risk Score to Improve Screening for Fracture Risk: A Genetic Risk Prediction Study
Affiliations
- PMID: 32614825
- DOI: 10.1371/journal.pmed.1003152
Abstract
Background: Since screening programs identify only a small proportion of the population as eligible for an intervention, genomic prediction of heritable risk factors could decrease the number needing to be screened by removing individuals at low genetic risk. We therefore tested whether a polygenic risk score for heel quantitative ultrasound speed of sound (SOS)-a heritable risk factor for osteoporotic fracture-can identify low-risk individuals who can safely be excluded from a fracture risk screening program.
Methods and findings: A polygenic risk score for SOS was trained and selected in 2 separate subsets of UK Biobank (comprising 341,449 and 5,335 individuals). The top-performing prediction model was termed "gSOS", and its utility in fracture risk screening was tested in 5 validation cohorts using the National Osteoporosis Guideline Group clinical guidelines (N = 10,522 eligible participants). All individuals were genome-wide genotyped and had measured fracture risk factors. Across the 5 cohorts, the average age ranged from 57 to 75 years, and 54% of studied individuals were women. The main outcomes were the sensitivity and specificity to correctly identify individuals requiring treatment with and without genetic prescreening. The reference standard was a bone mineral density (BMD)-based Fracture Risk Assessment Tool (FRAX) score. The secondary outcomes were the proportions of the screened population requiring clinical-risk-factor-based FRAX (CRF-FRAX) screening and BMD-based FRAX (BMD-FRAX) screening. gSOS was strongly correlated with measured SOS (r2 = 23.2%, 95% CI 22.7% to 23.7%). Without genetic prescreening, guideline recommendations achieved a sensitivity and specificity for correct treatment assignment of 99.6% and 97.1%, respectively, in the validation cohorts. However, 81% of the population required CRF-FRAX tests, and 37% required BMD-FRAX tests to achieve this accuracy. Using gSOS in prescreening and limiting further assessment to those with a low gSOS resulted in small changes to the sensitivity and specificity (93.4% and 98.5%, respectively), but the proportions of individuals requiring CRF-FRAX tests and BMD-FRAX tests were reduced by 37% and 41%, respectively. Study limitations include a reliance on cohorts of predominantly European ethnicity and use of a proxy of fracture risk.
Conclusions: Our results suggest that the use of a polygenic risk score in fracture risk screening could decrease the number of individuals requiring screening tests, including BMD measurement, while maintaining a high sensitivity and specificity to identify individuals who should be recommended an intervention.
Conflict of interest statement
I have read the journal’s policy and the authors of this manuscript have the following competing interests: JAK reports grants from Amgen, Eli Lilly and Radius Health; consulting fees from Theramex. JAK is the architect of FRAX but has no financial interest. JBR reports investigator-initiated grants from Biogen, Eli Lilly and GlaxoSmithKline, for programs unrelated to the research presented here. JBR is an advisor to GlaxoSmithKline. DPK reports grants from Radius Health and the Dairy Council unrelated to the research presented here and consulting fees from Solarea Bio unrelated to the research presented here. CC reports personal fees (outside the submitted work) from Amgen, Danone, Eli Lilly, GSK, Kyowa Kirin, Medtronic, Merck, Nestle, Novartis, Pfizer, Roche, Servier, Shire, Takeda, UCB. NCH reports consultancy, lecture fees and honoraria (outside the submitted work) from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma.
Similar articles
- Performance of fracture risk assessment tool in HIV-positive male individuals aged ≥45 years on suppressive antiretroviral therapy.J Int AIDS Soc. 2019 Aug;22(8):e25383. doi: 10.1002/jia2.25383.PMID: 31423752 Free PMC article.
- Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1. Epub 2008 Aug 28.PMID: 18751937
- Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool.J Bone Miner Res. 2010 May;25(5):1002-9. doi: 10.1002/jbmr.12.PMID: 20200927 Free PMC article.
- Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review.Turk J Urol. 2019 Feb 20;45(4):245-253. doi: 10.5152/tud.2019.11736. Print 2019 Jul.PMID: 30817274 Free PMC article. Review.
- A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.Arch Osteoporos. 2016 Dec;11(1):25. doi: 10.1007/s11657-016-0278-z. Epub 2016 Jul 27.PMID: 27465509 Free PMC article. Review.
No hay comentarios:
Publicar un comentario